Track record · closed signal

Encompass Health Corp (EHC) — closed signal from May 1, 2026

Partial Published before the outcome was known, scored automatically when the window closed on July 30, 2026 — +3.2% at the close.

Predicted vs. what happened

EHC price · publication thesis → realized outcomesplit-adjusted

$102.00 – $108.00Entry zone — fair-value band

$107.40Published — price the day we called it

$124.58Target — the price the thesis aimed for

$117.17Peak — highest point inside the window, not a realized return

$110.89Window close — end-of-window price, context only

What happened

Partial

Reached 57% of the predicted growth at its peak, without hitting the target.

At window close

+3.2%

realized, from the publication price to the last close inside the window

Peak gain

+9.1%

peak, from the publication price — not a realized return

S&P 500, same window

+3.2%

SPY over the identical days, dividend-adjusted

Window close

$110.89

last close inside the window, ended July 30, 2026

Peak price

$117.17

peak on July 28, 2026 — not a realized return

Days to target

—

The thesis — published May 1, 2026

Predicted growth

+16%

over the measurement window

Target price

$124.58

the price the thesis aimed for

Entry zone

$102.00 – $108.00

the fair-value band we waited for

Price at publication

$107.40

published May 1, 2026

Confidence

81%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Earnings came in better than expected and the company raised its outlook for the year, giving clearer visibility into future results. Demand for rehabilitation services tends to repeat, so revenue can be steady. The stock looks reasonably priced versus similar healthcare companies and offers defensive traits, but recent weak price action and high debt are reasons for caution.

Primary drivers

Earnings beat and higher guidance improved outlook visibility
Rehab services tend to have steady repeat demand
Valuation appears reasonable versus similar healthcare names
Recovery setup is getting better but debt levels add risk

How it played out

EHC: price rose 9.1% but missed the target

Lyra published EHC at $107.40 with an expected 16% rise. The thesis pointed to better-than-expected earnings, a higher full-year outlook, repeat demand for rehabilitation services, a reasonable valuation against similar healthcare companies, and defensive traits. It also noted weak recent price action and high debt as risks.

Inside the window, EHC rose to a peak of $117.17 on July 28, a 9.1% gain. That stayed below the $124.58 target, so the target was never reached. The stock ended the window at $110.89 on July 30. The thesis played out only partially. The price rose, but it did not deliver the expected 16% gain.

What happened during the window

On May 14, 2026, Encompass Health priced a $500 million private offering of senior notes due 2034. It said the proceeds were intended partly to redeem existing notes and repay revolving credit borrowings.

Encompass Health announces pricing of $500 million of senior notes due 2034 in a private offering

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All EHC signals